SCHEMBL16748612

SCHEMBL16748612

N#CCc1nc2ccccc2n1-c1nc(N)nc(Nc2ccc(OC(F)F)c(F)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 6/20 0.40
NPC1 O15118 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PIK3CA P42336 12/20 0.36
MTOR P42345 12/20 0.36
PIK3CD O00329 9/20 0.36
PIK3CB P42338 9/20 0.36
PIK3CG P48736 9/20 0.36
BRAF P15056 2/20 0.34
HIF1A Q16665 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RAF1 P04049 1/20 0.33
KDR P35968 1/20 0.33
TGFBR2 P37173 1/20 0.33
CSNK1D P48730 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740770 0.90 PIK3CB (0.40) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740761 0.89 BMI1 (0.49) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16748482 0.85 BMI1 (0.48) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740825 0.84 PIK3CB (0.44) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740856 0.81 BMI1 (0.50) BMI1PIK3CAMTORPIK3CDPIK3CB
SCHEMBL16740795 0.80 BMI1 (0.45) BMI1
SCHEMBL16740854 0.80 BMI1 (0.53) BMI1
SCHEMBL16748607 0.80 BMI1 (0.49) BMI1NPC1HTTRAB9ASMN1; SMN2
SCHEMBL16740781 0.78 BMI1 (0.38) BMI1NPC1HTTRAB9APIK3CA
SCHEMBL16740881 0.78 BMI1 (0.54) BMI1PIK3CAMTORPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885NPC1 2824/4885HTT 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.